{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-109437","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2026-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.078380+00:00","generated_at":"2026-05-15T10:34:29.411865+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kalaris reports positive Phase 1a TH103 data, $118M cash, net loss $43.4M in 2025","bullets":["Phase 1a in nAMD showed mean 10-letter BCVA gain, 129µm CST improvement, ~95% intraretinal fluid reduction.","TH103 plasma Cmax 27-51 fold lower than approved anti-VEGF agents; no DLTs or serious AEs observed.","Cash, equivalents and marketable securities $118.0M as of Dec 31, 2025; funding into Q4 2027.","Net loss $43.4M for 2025 vs $69.2M in 2024; R&D expense $30.8M, G&A $15.4M.","Completed $50.0M oversubscribed private placement in Dec 2025; Phase 1b/2 preliminary data expected 1H 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-109437","json":"https://secwatch.observer/filing/0001193125-26-109437.json","markdown":"https://secwatch.observer/filing/0001193125-26-109437.md","text":"https://secwatch.observer/filing/0001193125-26-109437.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526109437/0001193125-26-109437-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526109437/d124100d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T10:34:29.411865+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3cf17a3039261ee853ffd93c9356d96828de3c24","claim":"Kalaris Therapeutics, Inc. reported the year ended December 31, 2025 results: net income net loss was $43.4 million.","evidence_excerpt":"On March 17, 2026, Kalaris Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526109437/0001193125-26-109437-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Net income","value":"net loss was $43.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}